Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
US6767912B2 · kind B2 · utility
9Cited by
5References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2001 |
| Grant date | Jul 27, 2004 |
| Priority date | — |
| Expiry date | Mar 21, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.